Table 2.
Study and patient characteristics of end-stage organ disease patients undergoing bariatric surgery.
| Study | Number of latients | Age (Mean and standard deviation, except as indicated) | Male (n)/Female (n) | Etiology of End-Stage Organ Disease | Roux-en-Y Gastric Bypass (n) | Sleeve Gastrectomy (n) | Adjustable Gastric Band (n) | Bilio-pancreatic Diversion (n) | End-Stage Organ Disease-Specific Factors | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Heart Failure | |||||||||||||||
| NICM (n) | I CM (n) | Not Reported (n) | VAD Status Relative to Bariatric Surgery | ||||||||||||
| Pre- Bariatric Surgery (n) | Simultaneous (n) | No VAD (n) | |||||||||||||
| Amro | 1 | 34 | 1/0 | 1 | 0 | 0 | -- | -- | 1 | 0 | 0 | 1 | 0 | 0 | |
| Caceres | 1 | 56 | 0/1 | 1 | 0 | 0 | -- | -- | 1 | 0 | 0 | 0 | 1 | 0 | 0 |
| Chaudhry | 6 | median 34 (range 31–66)* | 3/3 | 4 | 2 | 0 | -- | -- | 0 | 6 | 0 | 0 | 3 | 0 | 3 |
| DeNino | 1 | 24 | 0/1 | 1 | 0 | 0 | -- | -- | 1 | 0 | 0 | 1 | 0 | 0 | |
| Gill | 2 | 24, 36 | 2/0 | 0 | 0 | -- | -- | 0 | 2 | 0 | 0 | 2 | 0 | ||
| Greene | 3 | 48.7 (SD 6.1) | 3/0 | 1 | 2 | 0 | -- | -- | 3 | 0 | 0 | 0 | 3 | 0 | 0 |
| Hawkins | 11 | 43.3 (SD not reported; range 31–66)* | 6/5 | 11 | 0 | 0 | -- | -- | 11 | 0 | 0 | 0 | 11 | 0 | 0 |
| Jeng | 1 | 25 | 1/0 | 1 | 0 | 0 | -- | -- | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Lim | 7 | 44.1 (SD 8.6) | 4/3 | 1 | 0 | -- | -- | 0 | 4 | 3 | 0 | 0 | 0 | 7 | |
| Lockard | 2 | 37, unclear | 2/0 | 0 | 0 | 2 | -- | -- | 2 | 0 | 0 | 0 | 1 | 1 | 0 |
| McQoskey | 14 | 46.2 (SD 9.2) | 10/4 | 10 | 4 | 0 | -- | -- | 11 | 2 | 1 | 0 | 0 | 0 | 14 |
| Punchai | 7 | 43.6 (SD 15.0) | 3/4 | 3 | 4 | 0 | -- | -- | 0 | 7 | 0 | 0 | 7 | 0 | 0 |
| Ramani | 12 | 41 (SD 10) | 3/9 | 10 | 2 | 0 | -- | -- | 9 | 2 | 1 | 0 | 0 | 0 | 12 |
| Ristow | 2 | 35, 36 | 1/1 | 2 | 0 | 0 | -- | -- | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Saeed | 1 | 50 | 1/0 | 1 | 0 | 0 | -- | -- | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Samaras | 2 | 42, 40 | 1/1 | 2 | 0 | 0 | -- | -- | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| Shah | 4 | 46.5 (SD 13.9) | 4/0 | 1 | 3 | 0 | -- | -- | 0 | 4 | 0 | 0 | 0 | 4 | 0 |
| Taylor | 1 | 57 | 0/1 | 0 | 1 | 0 | -- | -- | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Wikiel | 4 | 42.0 (SD 11.1) | 3/1 | 4 | 0 | 0 | -- | -- | 2 | 2 | 0 | 0 | 2 | 0 | 2 |
| TOTAL | 82 | 42.9 (SD 10.7) | 48 (58.5%)/34 (41.5%) | 61 (74.4%) | 19 (23.2%) | 2 (2.4%) | -- | -- | 41 (50.0%) | 30 (36.6%) | 10 (12.2%] | 1 (1.2%) | 31 (37.8%) | 8 (9.7%) | 3 (52.4%) |
| End-Stage Lung Disease | |||||||||||||||
| ILD (n) | IPF (n) | COPD (n) | |||||||||||||
| Ardila-Gatas | 25 | median 53 (IQR 42–58)* | 4/21 | 25 | 0 | 0 | -- | -- | 17 | 7 | 1 | 0 | -- | -- | -- |
| Martin | 1 | 48 | 0/1 | 1 | 0 | 0 | -- | -- | 1 | 0 | 0 | 0 | -- | -- | -- |
| Takata | 2 | 57, 59 | 2/0 | 0 | 1 | 1 | -- | -- | 0 | 2 | 0 | 0 | -- | -- | -- |
| TOTAL | 28 | 54.7 (SD 5.8) | 6 (21.4%)/22 (78.6%) | 26 (92.8%) | 1 (3.6%) | 1 (3.6%) | -- | -- | 18 (64.3%) | 9 (32.1%) | 1 (3.6%) | 0 (0%) | -- | -- | -- |
| Cirrhosis | |||||||||||||||
| HCV (n) | NASH (n) | Alcohol (n) | HBV (n) | Other (n) | Child’s Score | ||||||||||
| Class A (n) | Class (n) | Class C (n) | |||||||||||||
| Garcia-Sesma | 8 | 53.6 (8.1) | 2/6 | 2 | 5 | 1 | 0 | 0 | 0 | 8 | 0 | 0 | 6 | 2 | 0 |
| Sharpton | 32 | median 55 (IQR 50–61)* | 9/23 | 15 | 10 | 3 | 2 | 2 | 0 | 32 | 0 | 0 | 15 | 17 | 0 |
| Taneja | 1 | 29 | 1/0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| TOTAL | 41 | 50.9 (SD 11.2) | 12 (29.3%)/29 (70.7%) | 17 (41.5%) | 16 (39.0%) | 4 (9.7%) | 2 (4.9%) | 2 (4.9%) | 0 (0%) | 41 (100%) | 0 (0%) | 0 (0%) | 21 (51.2%) | 20 (48.8%) | 0 (0%) |
| Chronic Kidney Disease/End-Stage Renal Disease | |||||||||||||||
| Diabetes (n) | HTN (n) | FSGS (n) | GN (n) | Other/Unknown (n) | Desease Severity | ||||||||||
| CKD | ESRD | -- | |||||||||||||
| Adani | 3 | NR | NR | NR | NR | NR | NR | NR | 3 | 0 | 0 | 0 | NR | NR | -- |
| Al Sabah | 1 | 52 | 1/0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | -- |
| Al Bahri | 16 | 55.1 (SD 6.5) | 10/6 | 2*** | 1 | 1 | 1 | 12 | 3 | 0 | 0 | 16 | -- | ||
| Alexander | 41 | 44.4 (SD not reported)* | NR | NR | NR | NR | NR | NR | 41 | 0 | 0 | 0 | 32** | 0 | -- |
| Buch | 1 | 59 | 0/1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | -- |
| Carandina | 9 | 53.2 (SD 5.5) | 1/8 | 5 | 3 | 1 | 0 | 0 | 9 | 0 | 0 | 0 | 0 | 9 | -- |
| Contreras-Villamizar | 1 | 44 | 1/0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | -- |
| Jamal | 21 | 50.6 (SD 10.3) | 12/9 | 11 | 8 | 0 | 0 | 2 | 2 | 18 | 1 | 0 | 0 | 21 | -- |
| Kienzl-W | 8 | 48 (SD 13) | 3/5 | 3 | 0 | 0 | 1 | 4 | 8 | 0 | 0 | 0 | 0 | 8 | -- |
| Kim | 100 | median 50 (IQR 43.8 – 58.3)* | 41/59 | NR | NR | NR | NR | NR | 100 | 0 | 0 | 0 | 0 | 100 | -- |
| Koshy | 3 | 40.7 (11.9) | 2/1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 2 | -- |
| Lin | 6 | NR | NR | NR | NR | NR | NR | NR | 6 | 0 | 0 | 0 | 6 | 0 | -- |
| MacLaughlin | 9 | 46.1 (SD 7.0) | 3/6 | 1 | 3 | 2 | 0 | 3 | 9 | 0 | 0 | 0 | 4 | 5 | -- |
| Marszalek | 1 | 55 | 0/1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | -- |
| Newcombe | 3 | 43.7 (19.1) | 3/0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 3 | 0 | 1 | 2 | -- |
| Proczko | 3 | 55.0 (SD 6.0) | 1/2 | 2 | 1 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 3 | -- |
| Takata | 7 | 45.9 (SD 6.8) | 0/7 | 0 | 0 | 0 | 0 | 7 | 0 | 7 | 0 | 0 | 0 | 7 | -- |
| Thomas | 31 | 45 (SD 2.2) | 14/17 | 16 | 9 | 0 | 0 | 6 | 0 | 31 | 0 | 0 | 1 | 30 | -- |
| Yemeni | 24 | 54 (SD 3.1) | 16/8 | 15 | 0 | 2 | 7 | 17 | 7 | 0 | 0 | 0 | 24 | -- | |
| TOTAL | 288 | 49.7 (SD 7.4) | 108 (45.4%)/130 (54.6%) | 59 (46.8%) | 24 (19.0%) | 8 (6.3%) | 1 (0.8%) | 34 (27.0%) | 199 (69.1%) | 78 (27.1%) | 11 (3.8%) | 0 (0%) | 45 (16.3%) | 231 (83.7%) | -- |
*
Not included in calculation for group mean and standard deviation
**
Study reports 32 patients with CKD, but does not provide information on the remaining 9.
***
One of the patients was classified as having both diabetic nephropathy and hypertensive kidney disease SD – standard deviation; NICM – non-ischemic cardiomyopathy; ICM – ischemic cardiomyopathy; VAD – ventricular assist device; IQR – interquartile range; ILD – interstitial lung disease; IPF – idiopathic pulmonary fibrosis; COPD – chronic obstructive pulmonary disease; NASH – non-alcoholic steatohepatitis; HCV – hepatitis C virus; HBV – hepatitis B virus; CKD – chronic kidney disease; ESRD – end-stage renal disease; HTN – hypertension; FSGS – focal segmental glomerulosclerosis; NR – not reported